Comparison of pathologic response & safety in standard neoadjuvant therapy versus concomitant boost radiotherapy in patient with localy advanced rectal cancer.
Phase 2
Recruiting
- Conditions
- Rectal cancer.Malignant neoplasm of rectum
- Registration Number
- IRCT20211108052999N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Good performance (kps> 70)
T3,T4 N0 in 12 of anal verge
Node+
T2N0 in 5 cm of anal verge
No metastasis
Exclusion Criteria
Incomplete chemotherapy or radiotherapy
Recurrence
Chemotherapy before radiotherapy
Metastasis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathologic response. Timepoint: After surgery. Method of measurement: Tissue pathological assesment.;Treatment adverse effect. Timepoint: Weekly during treatment. Method of measurement: Examination, CBC and renal function test.
- Secondary Outcome Measures
Name Time Method Clinical response. Timepoint: Before intervention and before surgery. Method of measurement: MRI.